Genzyme Rejects Bid From Sanofi-Aventis
Are Biotechs Too Cheap? This morning people woke up to shares of Genzyme Corp. (NASDAQ:GENZ) trading sharply higher in pre-market trading. On Sunday, Genzyme received an $18.5 billion offer from Sanofi-Aventis (NYSE:SNY)…